Magainin-2

In 1999, the FDA advisory committee voted against Pexiganan (MSI-78) approval despite an 835-patient Phase III trial showing clinical cure rates comparable to oral ofloxacin for mildly infected diabetic foot ulcers. The primary concern was that Pexiganan was not demonstrated to be superior to existing treatments — the trial showed non-inferiority but the FDA panel wanted evidence of a distinct clinical advantage. Additionally, there were questions about whether a topical agent could adequately treat infections that might benefit from systemic therapy. A second Phase III trial was initiated by Dipexium Pharmaceuticals in 2014 but did not achieve its primary endpoint.

In 1987, Dr. Michael Zasloff, a physician-scientist at the National Institutes of Health, noticed that African clawed frogs (Xenopus laevis) recovered from surgical procedures without developing wound infections despite being returned to non-sterile aquarium water teeming with bacteria. This observation led him to investigate the frogs' skin secretions, where he isolated magainin-1 and magainin-2 — potent antimicrobial peptides that provided the frogs with a chemical shield against infection. The discovery launched an entirely new field of antimicrobial peptide research.

The toroidal pore model describes how magainin-2 disrupts bacterial membranes. When enough magainin-2 molecules accumulate on the membrane surface (reaching a critical peptide-to-lipid ratio), they insert into the bilayer and induce the lipid head groups to curve inward, forming barrel-shaped pores lined by both peptide molecules and lipid head groups — hence 'toroidal' or 'wormhole' shape. These pores are approximately 2-3 nm in diameter and allow uncontrolled ion leakage, dissipation of transmembrane potential, and rapid bacterial death. This is distinct from the barrel-stave model where pores are lined exclusively by peptide.

Resistance development is exceptionally difficult because magainin-2 targets the fundamental physical structure of bacterial membranes rather than a specific protein receptor or enzyme. To resist magainin, bacteria would need to fundamentally restructure their membrane lipid composition — replacing anionic phospholipids with neutral ones — which would compromise membrane function essential for survival. Serial passage experiments exposing bacteria to sub-inhibitory magainin concentrations for over 1,200 generations (equivalent to decades of clinical use) showed no significant resistance development.

Yes, magainin-2 shows selective anticancer activity because cancer cells, unlike normal mammalian cells, expose anionic phosphatidylserine (PS) on their outer membrane leaflet. Normal cells maintain PS on the inner leaflet, making their outer surface neutral and resistant to magainin binding. Cancer cells with exposed PS are targeted similarly to bacteria. Studies have shown cytotoxicity against bladder carcinoma, melanoma, and hematopoietic tumor cell lines at concentrations of 40-150 µg/mL, though this is higher than bactericidal concentrations.

Pexiganan (MSI-78) is a synthetic 22-amino-acid derivative of magainin-2 designed for enhanced antimicrobial potency. Key differences: Pexiganan has an amidated C-terminus for increased stability and a higher net positive charge through strategic lysine substitutions. These modifications improve membrane binding affinity and reduce the minimum inhibitory concentration from 80-160 µg/mL (magainin-2) to 1.25-40 µg/mL (Pexiganan) against clinical isolates — a 4-100 fold improvement in potency. Pexiganan retains the toroidal pore mechanism and low resistance potential of the parent compound.